

## Course Detail

# MMWR Weekly – February 4, 2011

**Course Number:** SS1747-020411

CE Origination Date: February 4, 2011

CE Expiration Date: March 21, 2011

## Presenters/Content Experts

### **Disparities in Diagnoses of HIV Infection between Blacks of African American and Other Racial/Ethnic Populations – 37 States, 2005-2008**

S Cohen, MPH, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Xiaohung Hu, MS, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Anna Satcher Johnson, MPH, BS, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Benjamin T. Laffoon, BS, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

Roy L. Shouse, MD, MPH, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC

### **Increase in Newly diagnosed HIV Infections Among Young Black Men Who have Sex with Men – Milwaukee County, Wisconsin, 1999-2008**

Jeanne Bertolli, PhD, MPH, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, CDC

Paul A. Biedrzycki, MPH, MBA, CIH, City of Milwaukee Health Department

Mari Gasiorowicz, MA, Wisconsin Division of Public Health

David C. Ham, MD, MPH, Experience Applied Epidemiology Fellowship, CDC

William L. Jeffries IV, PhD, MPH, EIS Officer, CDC

Carrie Nelsen, PhD, EIS Officer, CDC

Alexander M. Oster, MD, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, CDC

Thomas A. Peterman, MD, MSc, Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention

Travis Sanchez, DVM, MPH, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, CDC

Pilgrim S. Spikes, PhD, MSW, MPP, Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB prevention, CDC

Elizabeth A. Torrone, PhD, MSPH, EIS Officer, CDC

James M. Vergeront, MD, Wisconsin Division of Public Health, Department of Health Services

**Disclosure**

CDC, our planners, and our content experts wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dawn Smith's discussion of antiretroviral agents. She will be discussing guidance on the use of antiretroviral agents for the prevention of HIV infection among MSM. Medications have a labeled indication for the treatment of HIV infection but off-label use is permitted. Guidance is based on the results of a large clinical trial showing substantial efficacy for prevention. The pharmaceutical company is in discussions with FDA to apply for a prevention labeling indication. FDA has cleared the content of this interim guidance for off-label use. Dr. Paul Weidle has a discussion on pre-exposure prophylaxis. He will discuss the use of pre-exposure prophylaxis is not a FDA labeled indication for tenofovir/emtricitabine (Truvanda). Dr. Tejpatap Tiwari has a discussion on diphtheria antitoxin. He will be discussing FDA- licensed diphtheria antitoxin (DAT) product being unavailable for use in the USA since 1997. However, DAT is currently available for use under a FDA-approved Investigational New Drug Protocol which is managed by CDC. Physicians/health care providers can obtain DAT from CDC upon request for treatment of suspected diphtheria cases.

No commercial support.

Mechanism(s) to Resolve Real and Perceived Conflicts of Interest: Planner(s) reviewed content and it was cleared before publication.